IN Brief:
- Abbott announced plans on 21 October to separate its nutrition business into an independent listed company.
- The planned business comprises approximately $8.5bn in annual sales, 16,000 employees and 14 manufacturing sites.
- The separation is targeted for completion by end-2027 and remains subject to corporate and regulatory conditions.
Abbott plans to separate its global nutrition business into an independent publicly traded company with 14 manufacturing sites, approximately 16,000 employees and annual sales of around $8.5 billion. The proposed transaction would place well-established infant, children’s, medical and adult nutrition brands within a dedicated business, subject to the necessary approvals and completion procedures.
The US healthcare group announced the plan on 21 October, targeting completion by the end of 2027. Abbott intends to distribute shares in the new company to its existing shareholders, who would then hold interests in both businesses. The separation has not yet taken place and the nutrition operation will continue as part of Abbott while the process is under way.
The proposed company would include brands such as Similac, PediaSure, Pedialyte, Glucerna and Ensure. These products span distinct manufacturing categories, including infant formula and specialised nutritional drinks. The group has not published a plant-by-plant list defining the intended operational boundaries of the new company, and the company does not identify any factory closure or additional production site directly resulting from the separation.
The industrial scale of the proposal is significant. Fourteen manufacturing locations provide the future company with an established supply base across international markets, while the workforce figure shows that the separation would involve substantial production and supporting operations. Abbott said the new business would have the ability to direct investment towards product development, operational priorities and commercial growth in nutrition, without having to compete internally with its parent’s other technology and healthcare divisions for the same strategic resources.
Abbott chairman and chief executive Robert Ford said the transaction would allow each business to pursue its particular markets and investment requirements more independently. The parent company is expected to retain its medical devices, diagnostics and established pharmaceutical operations. Abbott estimates the remaining group would generate around $42 billion in sales following separation, although that estimate depends on the proposed corporate structure and the transaction completing as intended.
The nutrition business has continued to launch products during 2026. Abbott cited 10 introductions in the first half of the year, including a 42g-protein Ensure shake, a ready-to-feed US Similac infant formula made with whole milk and dye-free Pedialyte products. These examples illustrate areas where product formulation and manufacturing capability remain important to the group’s future strategy. They were not presented as separate factory investments announced in October.
Daniel Salvadori, currently an Abbott executive with experience across its pharmaceuticals and nutrition operations, has been named as the planned chief executive of the new nutrition company. His appointment would take effect within the proposed independent structure. Abbott has yet to report a completed transfer of assets and employees or a final listing arrangement.
The transaction is intended to qualify as a tax-free separation for US federal income tax purposes. It is subject to customary conditions, including regulatory approvals, an effective Form 10 registration statement and final authorisation from Abbott’s board. Abbott also expects one-off costs associated with the separation but has not quantified them, so the full transaction cost is not yet known.
Separating a global food and nutrition manufacturing operation requires decisions beyond the eventual share distribution. Quality systems, purchasing arrangements, regulatory obligations, research activity, technology infrastructure and supply contracts all need a workable operating structure. Abbott has not detailed how these services will be apportioned between the companies, nor whether transitional arrangements will be required. Their treatment should therefore be viewed as an implementation question rather than a settled outcome.
Abbott said the proposed separation would not change its 2026 financial guidance or the 2027 guidance it expects to provide in January. The business will remain within the group while preparatory work continues. The company has not set out the final allocation of individual manufacturing assets, supply agreements or shared services, leaving operational details to later transaction documentation.
For manufacturing customers, suppliers and employees, the principal confirmed development is a proposed change in ownership structure and management focus, not an immediate alteration to the 14-site production network. Further information about the locations, service arrangements, capital expenditure and operating governance will be needed as Abbott progresses towards its end-2027 target.
The proposed transaction also brings manufacturing continuity into focus. Nutrition products are produced under stringent safety, quality and regulatory requirements, and the separation will need to preserve clear responsibility for those controls as corporate structures change. The company has not said that manufacturing specifications, recipes or supplier contracts will be altered by the plan, and the October decision alone does not establish any immediate operational change at individual plants.
**Primary sources:** https://abbott.mediaroom.com/2026-10-21-Abbott-announces-its-intention-to-separate-its-global-Nutrition-business-into-an-independent,-publicly-traded-company ; https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/tm2627971d1_ex99-1.htm
